The stock of BioTelemetry, Inc. (NASDAQ:BEAT) is a huge mover today! About 778,451 shares traded hands or 156.18% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 49.88% since March 2, 2016 and is uptrending. It has outperformed by 41.62% the S&P500.
The move comes after 6 months positive chart setup for the $513.71M company. It was reported on Oct, 5 by Barchart.com. We have $31.66 PT which if reached, will make NASDAQ:BEAT worth $251.72 million more.
Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on November, 14. They expect $0.18 earnings per share, up 38.46% or $0.05 from last year’s $0.13 per share. BEAT’s profit will be $4.35 million for 29.51 P/E if the $0.18 EPS becomes a reality. After $0.20 actual earnings per share reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts -10.00% negative EPS growth.
BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage
Out of 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioTelemetry has been the topic of 2 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, September 13 by Sidoti. Dougherty & Company maintained BioTelemetry, Inc. (NASDAQ:BEAT) on Tuesday, July 28 with “Buy” rating.
According to Zacks Investment Research, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania.”
Insitutional Activity: The institutional sentiment increased to 1.48 in 2016 Q2. Its up 0.50, from 0.98 in 2016Q1. The ratio is positive, as 7 funds sold all BioTelemetry, Inc. shares owned while 43 reduced positions. 35 funds bought stakes while 39 increased positions. They now own 20.72 million shares or 1.56% less from 21.05 million shares in 2016Q1.
Mckinley Cap Ltd Liability Corp Delaware last reported 468,462 shares in the company. The California-based Schwab Charles Investment has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). California Pub Employees Retirement Sys last reported 160,100 shares in the company. The Ontario – Canada-based Hillsdale Mngmt has invested 0.13% in BioTelemetry, Inc. (NASDAQ:BEAT). Airain holds 25,762 shares or 0.02% of its portfolio. Argent Cap Mgmt reported 248,902 shares or 0.18% of all its holdings. Panagora Asset Mngmt holds 250,503 shares or 0.02% of its portfolio. Granite Point Management Lp holds 0.43% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 61,271 shares. The Illinois-based Oberweis Asset Mgmt has invested 0.21% in BioTelemetry, Inc. (NASDAQ:BEAT). Millrace Asset Inc holds 2.49% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 93,855 shares. Dimensional Fund Advsrs Limited Partnership has 1.29M shares for 0.01% of their US portfolio. Kalmar Invests De last reported 389,173 shares in the company. Vanguard Grp has 1.16 million shares for 0% of their US portfolio. Moreover, Menta Cap Ltd Liability Co has 0.07% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 31,902 shares. The Delaware-based Blackrock Advisors Ltd Liability has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT).
More notable recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Globenewswire.com which released: “BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom …” on August 23, 2016, also Globenewswire.com with their article: “BioTelemetry, Inc. Reports First Quarter 2016 Financial Results” published on April 26, 2016, Globenewswire.com published: “BioTelemetry, Inc. Announces Results of Tender Offer for Shares of …” on May 10, 2016. More interesting news about BioTelemetry, Inc. (NASDAQ:BEAT) were released by: Globenewswire.com and their article: “BioTelemetry, Inc. Announces the Completion of Its Acquisition of …” published on May 11, 2016 as well as Globenewswire.com‘s news article titled: “BioTelemetry, Inc. Appoints Colin Hill to Its Board of Directors” with publication date: May 06, 2016.
BEAT Company Profile
BioTelemetry, Inc. (BioTelemetry), incorporated on April 12, 2013, provides cardiac monitoring services, cardiac monitoring device manufacturing and cardiac laboratory services. The Firm operates through three divisions: Healthcare, Technology and Research. The Company’s subsidiary is CardioNet, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.